Stone Pharmaceutical Group: Received a milestone payment of $10 million from AstraZeneca under the strategic R&D cooperation agreement.

On August 5, the Stone Pharma Group announced on the Hong Kong Stock Exchange that it had received a milestone payment of $10 million from AstraZeneca on August 5, 2026, for exercising one of its authorized options under the terms of the agreement, marking steady progress in the relevant R&D work under the agreement as planned. The previous announcement disclosed that the Group agreed to discover preclinical candidate drugs with multi-indication disease treatment potential for several targets selected by AstraZeneca, including a preclinical small molecule oral therapy for immune diseases.